Skip to main content
Equibles
SKYI logo

SKYI · Sky Century Investment, Inc. · Metrics

Track SKYI — free

Use SKYI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SKYI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.06 -0.02 (-21.48%) At close · Nov 4
Rebalance outlook locked
Going-concern doubt — flagged Jul 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These and other factors raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification.”
View the 10-Q filed Jul 14, 2026
Market Cap
$382,838
Shares
6.94M
Volume · Nov 4 1000 Avg daily vol (3M) 7174

SKYI metrics

39 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.06
Market cap
$382,838

Price action

23 metrics
Price change (1W)
-18.1%
Price change (30D)
+0.0%
Price change (3M)
-69.3%
Price change (6M)
-95.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
850.8%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
43.6
Price vs SMA 50
-56.4%
Price vs SMA 200
—
Avg volume (3M)
7,174
Relative volume
0.1
Average dollar volume
$750

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
6.94M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.6×
reciprocal yield 17.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.0×
reciprocal yield 33.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
52.9%
Operating margin
-49.5%
Trailing 12 months
Net margin
-49.5%
Gross profit (TTM)
$66,794
Operating profit (TTM)
−$62,452
Net income (TTM)
−$62,452
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.04

Growth

11 metrics
Revenue growth YoY
+24.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$126,220
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+210.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-48.6%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$326,973
Latest balance sheet
Cash & equivalents
$264
Total assets
$128,573
Total debt
$327,237

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$56,700
Capital expenditures (TTM)
$17,400
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1555017 CUSIP 83084W203 Visit website Investor relations